Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.
MORGAN STANLEY: Here are the 10 healthcare companies that are most likely to get acquired in the next 12 months
MORGAN STANLEY: Here are the 10 healthcare companies that are most likely to get acquired in the next 12 months
Charlotte HuOct 26, 2018, 16:30 IST
Phil Walter/Getty Images
Advertisement
There's a slight slowing in the amount of healthcare M&A right now, even though 2018 started out strong.
The healthcare industry has historically been one of the most active sectors for deals. But a recent research report from Morgan Stanley said that analysts think high valuations of healthcare companies as well as a wealth of readily available funding for biotechs are limiting the number of takeovers.
Here are the top 10 healthcare companies Morgan Stanley analysts predict are most likely to receive tender offers in the next 12 months. Morgan Stanley used a proprietary quantitative model to make its predictions. It also excluded stocks that have been the subject of takeover rumors.
Company summary: Formerly IMS Health and Quintiles, IQVIA is now a multinational company that conducts contracted clinical research and provides health information technologies.
Company summary: BioMarin focuses on developing treatments for rare diseases. It recently launched Palynziq, which treats adult phenylketonuria, a rare inherited disorder in which the body can't process an amino acid called phenylalanine. Its pipeline also includes vosoritide (treats achondroplasia, a type of short-limbed dwarfism), val-rox (hemophilia A gene therapy), and BMN250 (treats Sanfilippo Syndrome B).
Company summary: Seattle Genetics is a biotech company that develops treatments for cancer. Its lead product is Adcetris, which treats different forms of blood and lymphatic cancers.
Company summary: Sarepta Therapeutics focuses on developing treatments for rare neuromuscular diseases. Its lead product is Exondys, which treats Duchenne muscular dystrophy.
